6. パーキンソン病
[臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03858270
(ClinicalTrials.gov)
April 1, 20192/10/2018Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, MemantineInhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, MemantineParkinson DiseaseDrug: Memantine;Other: PlaceboWayne State UniversityNULLRecruiting45 Years85 YearsAll50Phase 3United States
2NCT04470037
(ClinicalTrials.gov)
April 201626/5/2020Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative DisorderMultidisciplinary Study of Novel NMDA Modulation for Neurodegenerative DisorderParkinson's Disease With DementiaDrug: DAAOI-P;Drug: PlaceboChina Medical University HospitalMinistry of Science and Technology, TaiwanRecruiting50 Years90 YearsAll60Phase 2Taiwan
3NCT01785628
(ClinicalTrials.gov)
August 201024/6/2011The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's DiseaseParkinson's Disease With DementiaDietary Supplement: Sarcosine Capsule;Dietary Supplement: Placebo CapsuleChina Medical University HospitalNational Science Council, TaiwanCompletedN/AN/AAll30N/ATaiwan
4NCT00163085
(ClinicalTrials.gov)
May 20059/9/2005The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Explore The Efficacy And Safety Of The NR2B NMDA Antagonist CP-101,606 In Patients With Idiopathic Parkinson's DiseaseParkinson's DiseaseDrug: NR2B NMDA Antagonist CP-101,606 (traxoprodil)PfizerNULLCompleted30 Years80 YearsBoth12Phase 2United States
5NCT00375778
(ClinicalTrials.gov)
April 200512/9/2006Parkinson's Disease Evaluated by PET and the Effect of MemantineParkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDA Receptor Antagonist MemantineParkinson's DiseaseDrug: memantine (drug)University of AarhusLundbeck FoundationCompleted50 Years70 YearsBoth12N/ADenmark
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00001929
(ClinicalTrials.gov)
March 19993/11/1999Treatment of Parkinson's Disease With EliprodilNMDA-Receptor Blockade With Eliprodil in Parkinson's DiseaseMovement Disorders;Parkinson DiseaseDrug: EliprodilNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth20Phase 2United States
7NCT00001365
(ClinicalTrials.gov)
July 19933/11/1999Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous SystemNMDA Receptor Antagonist Treatment of Neurodegenerative DiseaseNeurodegenerative Disease;Parkinson's DiseaseDrug: dextromethorphanNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth42Phase 2United States